Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
2320 Scientific Park Drive, Wilmington, NC, 28405, US
Alcami is a US contract development and manufacturing organization with 45+ years of experience advancing pharmaceuticals and biologics from development to delivery. Alcami provides fully integrated lab services, drug product manufacturing, and cGMP pharma storage and support services including calibration, validation and environmental monitoring.
Gain insights into the parenteral and fill-finish manufacturing markets, opportunities, and recent investments in the space.
Released By Alcami Corporation
Alcami used a Gerteis Mini-Pactor® roller compactor to develop a capsule formulation and critical processing parameters at the target dosage in record time.
25-year industry professional brings a track record of leading high-performing, client-centered business teams.
A $31 million investment will expand its sterile development and manufacturing operation in Charleston, SC.
Chad Bovero, James Fife, and Tobin Cowart promoted to senior leadership team.
Alcami to manufacture PharmaTher’s proprietary ketamine products for FDA Phase 3 clinical studies and global commercialization.
Sign up to get a close-up look at our US network of laboratories and hear about our expansion plans.
The agreement represents another step toward the proprietary manufacturing, formulation, and delivery of products for Tryp’s PFNTM program.
In this webinar, Alcami’s Brent Harlow will guide you through the necessity of these studies and how to successfully perform them for FDA approval.
Due to the high costs and low demands of the drug product, it is important to efficiently use API supply during the formulation process.
WHO, FDA and the European Pharmacopoeia have established strict regulatory guidelines to guarantee product quality in biologics.
He succeeds Walter J. Kaczmarek III, who is stepping down as Chief Executive Officer.
Formulation and Method Development.
Parenteral Forms.
Wether you are a virtual start-up or a large organization, you and your patients deserve subject matter experts who take ownership of your program from clinical trals through commerical supply. Partnering with Alcami as your contract development and manufacturing organization connects you to a US-based team of dedicated professionals with over 40 years experience advancing […]
Emerging Technology Needs and Value Proposition for Strategic Partnerships with Contract Development and Manufacturing Organizations (CDMOs)
Alcami, a leading United States-based contract development and manufacturing organization (CDMO), announced an additional $2 million investment to expand its oral solid development and manufacturing capabilities in Wilmington, NC. The investment will add a Gerteis Mini-Pactor® roller compactor and low humidity suites to Alcami’s existing 140,000 square foot campus in Wilmington, NC. The expansion, which is on track to be completed in the first […]
High-resolution mass spectrometry is a key component in the characterization of novel biologics and biosimilars.
Alternate methods of administering solid oral formulations are necessary to meet the needs of all patients.
by Chris Williams, Julia Spraul (pictured), and Alyssa McBurney
Why pharma needs automated AI security now.
By: Frank Balonis
Welcomes Brian Riley as President and Chief Technical Officer, Joanne Lager, MD as Chief Medical Officer, and Adrian Chaisson as Chief of Staff.
By: Charlie Sternberg
Dr. Abdul Mutlib is appointed the President of Frontage Laboratories, Canada, and will spearhead growth as he continues to serve as Chief Scientific & Strategy Officer.
By: Rachel Klemovitch
Strengthens BioMarin's enzyme therapies portfolio, adding a late-stage enzyme replacement therapy, INZ-701.
Forms a rare tumor business for Merck KGaA, Darmstadt, Germany, including SpringWorks’ portfolio and pimicotinib.
The U.S. launch of Conexxence and Bomyntra follows the FDA’s approval in March 2025.
Richard Thakor and Daniel Anderson will speak at the event in November.
Strengthens its global particle engineering capabilities.
Will manufacture SurVaxM, a novel immunotherapeutic vaccine designed to treat glioblastoma, for use in clinical trials.
Integrate Keystone’s Key-Pak child-resistant blister cards with Med-Con’s medication adherence prompting and monitoring application.
The company is investing $90 million to expand two U.S. facilities to enhance capacity and efficiency.
Villain offers extensive expertise in peptide and oligonucleotide development and manufacturing.
Collaboration aims to discover and develop novel therapeutics for cardiovascular disease using Novartis’ ProFoundry Platform.
It is the only ready-to-use liquid immunoglobulin therapy with (IgA) content and is set for commercialization in 2026.
The companies have released the first batch of Novalgen’s next-generation T-cell engager for first in-human clinical trials.
The collaboration now is progressing to the in vivo preclinical stage.
Will further expand its domestic capabilities to develop, produce and deliver medicines.
EVP & COO Todd Nelson reflects on Porton J-STAR's defining milestones, global network strategy, and what’s ahead as the company enters its third decade.
Released By Porton
The clinical site is expected to be completed and ready for media fill by the end of 2029.
The company’s label updates are for its CAR T cell therapies, Breyanzi and Abecma.
Is purpose-built for manufacturing high-quality plasmid DNA and viral vectors.
Partnership expected to improve yield and upgrade analytical methods ahead of clinical use and regulatory submissions.
Hervé Hoppenot will retire after 11 years of leading the company through major expansion.
Will commence cell therapy process development and clinical manufacturing services at AGC Inc.’s Yokohama Technical Center.
Agreement to support future studies investigating the combination of ateganosine and atezolizumab for safe and effective cancer treatments.
Will develop and commercialize a potential treatment for obesity and metabolic disease based on technology licensed from the U.S. Department of Veterans Affairs.
Addressing increasing complexity, cost of drug development, and navigating regulatory compliance.
By: Kristin Brooks
ST16 Semi-Automated Aggregation Station combines software and flexible hardware to help optimize productivity, improve operational efficiency and streamline processes.
This strategic partnership provides end-to-end visibility and best-in-class track and trace for Praxis’s customer base.
This integrated solution follows the company’s acquisition of Pharmacontrol Electronic and combines technologies.
This acquisition enhances Systech’s product offerings and enables it to offer a more comprehensive product portfolio to its customers.
Offers quick compliance, avoids delays, and optimizes production with multi-scan and mobile flexibility.
Pharmaceutical service provider expands its footprint in the greater Chicago area.
Released By Vetter Pharma International
As the pharmaceutical industry continues to evolve, so too does the role of secondary packaging.
An independent jury of experts will evaluate entries based on scientific merit, feasibility, and potential patient impact.
The company opened a new GMP Pilot Unit to produce liquid and lyophilized injectable forms.
Released By Nelson Laboratories, LLC
Aims to discover, develop, and commercialize oral small molecule therapeutics directed at a novel non-incretin GPCR target for cardiometabolic diseases.
This expansion will change the trajectory of MASH by focusing on early detection, diagnosis, and access to care.
Approved for the detection and localization of prostate-specific membrane antigen (PSMA)-positive lesions in adults with prostate cancer.
Will help enable broader adoption of advanced manufacturing technologies and state-of-the-art quality solutions
Released By Mikart
ATP-bioluminescence and regulatory advancements address unmet manufacturing and testing needs.
By: Brice Chasey
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !
